Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease

Launched by CHINA NATIONAL CENTER FOR CARDIOVASCULAR DISEASES · Apr 2, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for patients with coronary artery disease who also have a condition called moderate ischemic mitral regurgitation (IMR). IMR happens when the heart's mitral valve doesn't close properly, causing blood to flow backward. The researchers want to see if a medication called an angiotensin receptor/neprilysin inhibitor (ARNI) can help improve this condition in patients who are undergoing a specific heart surgery called coronary artery bypass grafting (CABG).

To be eligible for the trial, participants must be between the ages of 65 and 74, have given their consent to join, and have been diagnosed with moderate IMR based on two heart ultrasound tests before their surgery. However, there are some health conditions that could exclude someone from participating, such as very low blood pressure or kidney problems. Those who join will receive the study treatment and will be monitored to see how well it works. It’s important for potential participants to know that this trial is not yet recruiting, meaning it will start enrolling patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Fully informed and voluntarily signed informed consent;
• • 2. Received CABG and moderate IMR was diagnosed on two consecutive preoperative transthoracic echocardiography (according to 2021 ESC/EACTS Guidance Standards )
• Exclusion Criteria:
• • 1.Symptomatic hypotension and/or a SBP \< 100 mmHg at screening; 2.Estimated GFR \< 30 mL/min/1.73m2; 3.Serum potassium \> 5 mmol/L at screening; 4.History of angioedema or unacceptable side effects while receiving ACE inhibitors or ARBs; 5.Patients receiving mitral valve intervention at the same time, or have participated in other clinical trials, or are unwilling to participate in this study.